There is a rising interest and awareness in health and nutrition, where consumers seek ways to improve digestive, immune, and overall health.[1] High consumer awareness together with prevalent marketing are the major factors driving the demand for synbiotic products, as the growing health consciousness among consumers is expected to drive market growth in synbiotics, with a projected annual growth rate of 8.3% from 2020 to 2027 globally.[2]

• Bimuno[®] GOS and Probi Defendum[® ]which demonstrate a clear synergistic synbiotic combination as the probiotic strains in Probi Defendum selectively utilize the prebiotic GOS to enhance the production of short chain fatty acids.
• Bimuno[®] GOS and Probi Digestis[® ]that showcases complementary mechanisms of action and enter the market as the most researched synbiotic ingredient pairing, with extensive studies behind both ingredients covering almost 340 publications between them.

"In today's health and wellness market, consumers seek scientifically backed products that they can trust, and our collaborative launch with Clasado positions us in the forefront of the growing synbiotic market, based on research and empirical evidence. Probi Digestis and Probi Defendum are extensively studied probiotic concepts, and we look forward to advancing the wider synbiotic category with our evidence-based approach", says Anita Johansen CEO of Probi.

"The biotics category is experiencing an unprecedented era of growth and discovery, and we are thrilled to reveal our synbiotic combinations in partnership with Probi, at SupplySide West. By synergizing our expertise, we are taking the guesswork away for formulators with predetermined and scientifically backed combinations, based on the most comprehensively studied ingredients of their kind. This unlocks faster speed to market, as well as more reliable results", says Per Rehné, CEO of Clasado.

To uncover the benefits of the concepts, you are welcome to visit Probi at booth #5851, and Clasado at booth #5605, during SupplySide West, 25[th] - 26[th] of October.

Synbiotic Fast Facts

Synbiotic's is defined as "a mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host".[3] Furthermore, a synbiotic solution can be either synergistic or complementary. A synergistic synbiotic is a solution where "the substrate is designed to be selectively utilized by the co-administered microorganism(s)"[3], in this case the solution is composed of a prebiotic and a probiotic that selectively nourish each other and results in a stronger health benefit in the host, than what can be seen by one of the ingredients alone. "A complementary synbiotic is a synbiotic composed of a probiotic combined with a prebiotic, which is designed to target autochthonous microorganisms".[3] in this case defined as a prebiotic and probiotic working side by side, each of them delivering their proposed health benefit to the host. According to the definitions by ISAPP[3 ]it is required that both the prebiotic and the probiotic must meet the minimal requirements defined for each component.

[1 ]FMI Synbiotics products market June 2022

[2] Synbiotic Product Market Size | Industry Growth Report, 2027 (grandviewresearch.com) (https://www.grandviewresearch.com/industry-analysis/synbiotic-product-market)

[2] International Scientific Association for Probiotics and Prebiotics (ISAPP)

For further information, please contact:

Anita Johansen, CEO, Probi, Phone: +46 46 286 89 48, E-mail: anita.johansen@probi.com
Christina Vegge, Senior Director R&D, Probi, Phone +46 733 00 43 56, E-mail: christina.vegge@probi.com

ABOUT PROBI

Probi[®] is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.